| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Minimally invasive fetal therapy
DOI: 10.1016/j.bpobgyn.2012.03.005
The implementation of systematic pregnancy screening programmes, and the increased use and improving quality of medical imaging techniques, have lead to earlier detection and better understanding of t...
|
Tim van Mieghem,
David Baud,
Roland Devlieger,
Liesbeth Lewi,
Greg Ryan,
Luc De Catte,
Jan Deprest
et al.
|
Full-length article
(In Press Uncorrected Proof)
|
25 May 2012 |
|
Microbicides in Obstetrics and Gynaecology – Answers to Multiple Choice Questions for Vol. 26, No. 4
DOI: 10.1016/j.bpobgyn.2012.05.003
|
|
Miscellaneous
(In Press Uncorrected Proof)
|
24 May 2012 |
|
Microbicides in Obstetrics and Gynaecology – Multiple Choice Questions for Vol. 26, No. 4
DOI: 10.1016/j.bpobgyn.2012.05.002
|
|
Miscellaneous
(In Press Uncorrected Proof)
|
23 May 2012 |
|
Obstetric outcome and long-term follow up of children conceived through assisted reproduction
DOI: 10.1016/j.bpobgyn.2012.05.001
Most children born after assisted reproduction techniques are healthy. The most important risk associated with in-vitro fertilisation is the higher multiple birth rate, which may result in increased c...
|
Christina Bergh,
Ulla-Britt Wennerholm
|
Full-length article
(In Press Uncorrected Proof)
|
21 May 2012 |
|
Role of reproductive surgery in the era of assisted reproductive technology
DOI: 10.1016/j.bpobgyn.2012.04.003
Reproductive surgery could be divided into surgery as a primary treatment for infertility, surgery to enhance in-vitro fertilisation outcome, and surgery for fertility preservation. A shift has occurr...
|
Togas Tulandi,
Khalid Akkour
|
Full-length article
(In Press Uncorrected Proof)
|
18 May 2012 |
|
Prevention and management of ovarian hyperstimulation syndrome
DOI: 10.1016/j.bpobgyn.2012.04.004
Ovarian hyperstimulation syndrome is a relatively common complication of ovarian stimulation and can be life-threatening. The pathophysiology of ovarian hyperstimulation syndrome is characterised by i...
|
Chin-Der Chen,
Shee-Uan Chen,
Yu-Shih Yang
|
Full-length article
(In Press Uncorrected Proof)
|
18 May 2012 |
|
Ethical issues in infertility treatment
DOI: 10.1016/j.bpobgyn.2012.04.002
Two currently contentious domains in infertility treatment are discussed: assisted reproduction for same-sex couples and fertility preservation for women with cancer. Despite an increasing recognition...
|
Guido Pennings,
Heidi Mertes
|
Full-length article
(In Press Corrected Proof)
|
07 May 2012 |
|
Reproductive decisions after fetal genetic counselling
DOI: 10.1016/j.bpobgyn.2012.04.001
A broad range of testing modalities for fetal genetic disease has been established. These include consisting of carrier screening for single-gene mutations, first-trimester and second-trimester screen...
|
Eugene Pergament,
Deborah Pergament
|
Full-length article
(In Press Uncorrected Proof)
|
30 April 2012 |
|
Maternal–fetal surgery for structural malformations
DOI: 10.1016/j.bpobgyn.2012.03.003
Although most prenatally diagnosed correctable anatomic abnormalities are best addressed by surgical interventions after birth, the outcomes of a small number of severe structural malformations with p...
|
Emily A. Partridge,
Alan W. Flake
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Uses of cell free fetal DNA in maternal circulation
DOI: 10.1016/j.bpobgyn.2012.03.004
For over a decade, researchers have focused their attention on the development of non-invasive prenatal diagnosis tests based on cell-free fetal DNA circulating in maternal blood. With the possibility...
|
Melissa Hill,
Angela N. Barrett,
Helen White,
Lyn S. Chitty
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Fertility Preservation in Gynaecological Cancer – Answers to Multiple Choice Questions for Vol. 26, No. 3
DOI: 10.1016/j.bpobgyn.2012.03.002
|
|
Miscellaneous
(In Press Corrected Proof)
|
04 April 2012 |
|
Preface
DOI: 10.1016/j.bpobgyn.2012.02.003
It is almost 3 decades since the first cases of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) were reported, yet there is no cure or vaccine. Although the HIV incid...
|
Jagidesa Moodley
|
Editorial
(In Press Corrected Proof)
|
29 March 2012 |
|
Implementing microbicides in low-income countries
DOI: 10.1016/j.bpobgyn.2012.02.004
The magnitude of the global human immunodeficiency virus (HIV) epidemic is determined by women from lower income countries, specifically sub-Saharan Africa. Microbicides offer women who are unable to ...
|
Tanuja N. Gengiah,
Quarraisha Abdool Karim
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
Vaginal microbicides to prevent human immunodeficiency virus infection in women: Perspectives on the female genital tract, sexual maturity and mucosal inflammation
DOI: 10.1016/j.bpobgyn.2012.02.002
Topically applied vaginal microbicides to protect against human immunodeficiency (HIV) virus infection offer an important female-controlled prevention strategy. Microbicides have been in development f...
|
Lindi Roberts,
Lenine Liebenberg,
Shaun Barnabas,
Jo-Ann Passmore
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Future strategies in microbicide development
DOI: 10.1016/j.bpobgyn.2012.02.001
The reduction in human immunodeficiency virus (HIV) infection in women demonstrated by pericoital use of tenofovir gel has encouraged the continued development of microbicides. Novel approaches includ...
|
Zeda F. Rosenberg,
Brid Devlin
|
Full-length article
(In Press Corrected Proof)
|
02 March 2012 |
|
Overview of microbicides for the prevention of human immunodeficiency virus
DOI: 10.1016/j.bpobgyn.2012.01.010
Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmi...
|
Salim S. Abdool Karim,
Cheryl Baxter
|
Full-length article
(In Press Corrected Proof)
|
23 February 2012 |
|
Contraception and pregnancy in microbicide trials
DOI: 10.1016/j.bpobgyn.2012.01.005
The distinctive feature of the human immunodeficiency virus (HIV) epidemic in Sub-Saharan Africa is the burden on women, in particular young women of reproductive age. Consequently, most late-phase ef...
|
Sengeziwe Sibeko,
Gabriel M. Cohen,
Jagidesa Moodley
|
Full-length article
(In Press Corrected Proof)
|
06 February 2012 |
|
Empowering women in human immunodeficiency virus prevention
DOI: 10.1016/j.bpobgyn.2012.01.006
Women comprise one-half of people infected with the human immunodeficiency virus in the world, and about 70% of them live in sub-Saharan Africa. Advancing, untreated HIV disease in women has resulted ...
|
Quarraisha Abdool Karim,
Hilton Humphries,
Zena Stein
|
Full-length article
(In Press Corrected Proof)
|
03 February 2012 |
|
Formulation, pharmacokinetics and pharmacodynamics of topical microbicides
DOI: 10.1016/j.bpobgyn.2012.01.004
The development of safe topical microbicides that effectively prevent human immunodeficiency virus (HIV) infection is a major goal in curbing the human immunodeficiency virus pandemic. A number of pas...
|
Jessica L. Adams,
Angela D.M. Kashuba
|
Full-length article
(In Press Corrected Proof)
|
25 January 2012 |
|
Statistical and methodological issues in microbicide trial design
DOI: 10.1016/j.bpobgyn.2011.12.008
Microbicide trials aim to measure the effect of a microbicide in reducing the risk of acquiring human immunodeficiency virus. Such trials present a number of challenging issues from design and conduct...
|
Angela M. Crook,
Andrew J. Nunn
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |